» Articles » PMID: 33433580

Glaucoma in Adults-Screening, Diagnosis, and Management: A Review

Overview
Journal JAMA
Specialty General Medicine
Date 2021 Jan 12
PMID 33433580
Citations 198
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Glaucoma is the most common cause of irreversible blindness worldwide. Many patients with glaucoma are asymptomatic early in the disease course. Primary care clinicians should know which patients to refer to an eye care professional for a complete eye examination to check for signs of glaucoma and to determine what systemic conditions or medications can increase a patient's risk of glaucoma. Open-angle and narrow-angle forms of glaucoma are reviewed, including a description of the pathophysiology, risk factors, screening, disease monitoring, and treatment options.

Observations: Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision. Intraocular pressure is the only known modifiable risk factor. Other important risk factors include older age, nonwhite race, and a family history of glaucoma. Several systemic medical conditions and medications including corticosteroids, anticholinergics, certain antidepressants, and topiramate may predispose patients to glaucoma. There are 2 broad categories of glaucoma, open-angle and angle-closure glaucoma. Diagnostic testing to assess for glaucoma and to monitor for disease progression includes measurement of intraocular pressure, perimetry, and optical coherence tomography. Treatment of glaucoma involves lowering intraocular pressure. This can be achieved with various classes of glaucoma medications as well as laser and incisional surgical procedures.

Conclusions And Relevance: Vision loss from glaucoma can be minimized by recognizing systemic conditions and medications that increase a patient's risk of glaucoma and referring high-risk patients for a complete ophthalmologic examination. Clinicians should ensure that patients remain adherent with taking glaucoma medications and should monitor for adverse events from medical or surgical interventions used to treat glaucoma.

Citing Articles

Association between 91 circulating inflammatory proteins and the risk of glaucoma: A Mendelian randomization study.

Xu W, Fan Q, Meng Y, Nie Z, Sawut A, Xie S Sci Rep. 2025; 15(1):8876.

PMID: 40087334 DOI: 10.1038/s41598-025-92153-y.


Structural basis for anomalous cellular trafficking behavior of glaucoma-associated A427T mutant myocilin.

Hill K, Scelsi H, Youngblood H, Faralli J, Itakura T, Fini M bioRxiv. 2025; .

PMID: 40060664 PMC: 11888440. DOI: 10.1101/2025.02.26.640437.


AI for glaucoma, Are we reporting well? a systematic literature review of DECIDE-AI checklist adherence.

Leonard-Hawkhead B, Higgins B, Wright D, Azuara-Blanco A Eye (Lond). 2025; .

PMID: 39966602 DOI: 10.1038/s41433-025-03678-5.


Lung Function as a Biomarker for Glaucoma: The UK Biobank Study.

Yu J, Zhang Y, Kam K, Ho M, Young A, Pang C Invest Ophthalmol Vis Sci. 2025; 66(2):48.

PMID: 39964321 PMC: 11838118. DOI: 10.1167/iovs.66.2.48.


Association between self-reported eye conditions in patients at rural federally qualified health centers and vision-targeted health-related quality of life: the AL-SIGHT study.

Swain T, McGwin G, Rhodes L, Girkin C, Owsley C Front Med (Lausanne). 2025; 12:1498413.

PMID: 39881846 PMC: 11774997. DOI: 10.3389/fmed.2025.1498413.